Welgus Howard G. 4
4 · Arcutis Biotherapeutics, Inc. · Filed Mar 4, 2026
Insider Transaction Report
Form 4
Welgus Howard G.
Director
Transactions
- Sale
Common Stock
[F1][F2]2026-03-02$25.65/sh−10,000$256,518→ 49,744 total
Footnotes (2)
- [F1]The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted on March 11, 2025, by the Reporting Person, with a plan end date of May 29, 2026.
- [F2]The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $25.37 to $26.10, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Signature
/s/ Latha Vairavan, as Attorney-in-Fact for Howard G. Welgus|2026-03-04